Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Z3RF
|
|||
| Former ID |
DIB001019
|
|||
| Drug Name |
UCB-11056
|
|||
| Synonyms |
127390-77-6; Ucb-11056; Ucb 11056; 2-(4-morpholino-6-propyl-1,3,5-triazin-2-yl)aminoethanol; UNII-MU6BC50P47; MU6BC50P47; 2-((4-Morpholino-6-propyl-1,3,5-triazin-2-yl)amino)ethanol; 2-((4-(4-Morpholinyl)-6-propyl-1,3,5-triazin-2-yl)amino)ethanol; Ethanol,2-[[4-(4-morpholinyl)-6-propyl-1,3,5-triazin-2-yl]amino]-; Ethanol, 2-((4-(4-morpholinyl)-6-propyl-1,3,5-triazin-2-yl)amino)-; NERMEVBNTXXDNG-UHFFFAOYSA-N; ACMC-20msf9; AC1L2Y9Y; SCHEMBL3365592; CTK4B5589; DTXSID60155545; ZINC3803539
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Cognitive impairment [ICD-11: 6D71; ICD-10: F06.7] | Phase 2 | [1] | |
| Company |
UCB Pharma SA
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C12H21N5O2
|
|||
| Canonical SMILES |
CCCC1=NC(=NC(=N1)N2CCOCC2)NCCO
|
|||
| InChI |
1S/C12H21N5O2/c1-2-3-10-14-11(13-4-7-18)16-12(15-10)17-5-8-19-9-6-17/h18H,2-9H2,1H3,(H,13,14,15,16)
|
|||
| InChIKey |
NERMEVBNTXXDNG-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 127390-77-6
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | cAMP formation (cAMP form) | Target Info | Modulator | [1], [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Relationship between urinary sodium excretion and pioglitazone-induced edema. J Diabetes Investig. 2010 Oct 19;1(5):208-11. | |||
| REF 2 | ucb 11056, a new potential nootropic drug, amplifies induced cyclic AMP formation in rat brain tissue. J Neurochem. 1993 Dec;61(6):2256-61. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.